Citalopram/pipamperone - PharmaNeuroBoost

Drug Profile

Citalopram/pipamperone - PharmaNeuroBoost

Alternative Names: Pipamperone/citalopram; PipCit; PNB-01

Latest Information Update: 01 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PharmaNeuroBoost
  • Class Antidepressants; Antipsychotics; Benzofurans; Butyrophenones; Nitriles; Propylamines; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Dopamine D4 receptor antagonists; Serotonin 2A receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Major depressive disorder

Most Recent Events

  • 01 Sep 2015 No recent reports on development identified - Phase-III for Major depressive disorder in USA and Canada (PO)
  • 01 Sep 2015 No recent reports on development identified - Phase-II for Major depressive disorder in United Kingdom (PO)
  • 01 Dec 2012 PharmaNeuroBoost N.V. completes a phase III trial in Major Depressive Disorder in USA and Canada (PO) (NCT01312922)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top